Literature DB >> 24127294

Design and generation of highly diverse fluorinated fragment libraries and their efficient screening with improved (19) F NMR methodology.

Anna Vulpetti1, Claudio Dalvit.   

Abstract

Fragment screening performed with (19) F NMR spectroscopy is becoming increasingly popular in drug discovery projects. With this approach, libraries of fluorinated fragments are first screened using the direct-mode format of the assay. The choice of fluorinated motifs present in the library is fundamental in order to ensure a large coverage of chemical space and local environment of fluorine (LEF). Mono- and poly-fluorinated fragments to be included in the libraries for screening are selected from both in-house and commercial collections, and those that are ad hoc designed and synthesized. Additional fluorinated motifs to be included in the libraries derive from the fragmentation of compounds in development and launched on the market, and compounds contained in other databases (such as Integrity, PDB and ChEMBL). Complex mixtures of highly diverse fluorine motifs can be rapidly screened and deconvoluted in the same NMR tube with a novel on the fly combined procedure for the identification of the active molecule(s). Issues and problems encountered in the design, generation and screening of diverse fragment libraries of fluorinated compounds with (19) F NMR spectroscopy are analyzed and technical solutions are provided to overcome them. The versatile screening methodology described here can be efficiently applied in laboratories with limited NMR setup and could potentially lead to the increasing role of (19) F NMR in the hit identification and lead optimization phases of drug discovery projects.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  fluorinated fragments; fluorine NMR spectroscopy; fragment-based drug discovery; libraries; local environment of fluorine (LEF); screening

Mesh:

Substances:

Year:  2013        PMID: 24127294     DOI: 10.1002/cmdc.201300351

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  8 in total

Review 1.  Twenty years on: the impact of fragments on drug discovery.

Authors:  Daniel A Erlanson; Stephen W Fesik; Roderick E Hubbard; Wolfgang Jahnke; Harren Jhoti
Journal:  Nat Rev Drug Discov       Date:  2016-07-15       Impact factor: 84.694

2.  Synthetic biology approaches to fluorinated polyketides.

Authors:  Benjamin W Thuronyi; Michelle C Y Chang
Journal:  Acc Chem Res       Date:  2015-02-26       Impact factor: 22.384

3.  Parallelized Ligand Screening Using Dissolution Dynamic Nuclear Polarization.

Authors:  Yaewon Kim; Mengxiao Liu; Christian Hilty
Journal:  Anal Chem       Date:  2016-10-25       Impact factor: 6.986

4.  19F-Tagged metal binding pharmacophores for NMR screening of metalloenzymes.

Authors:  Kathleen E Prosser; Alysia J Kohlbrand; Hyeonglim Seo; Mark Kalaj; Seth M Cohen
Journal:  Chem Commun (Camb)       Date:  2021-05-18       Impact factor: 6.222

Review 5.  Current NMR Techniques for Structure-Based Drug Discovery.

Authors:  Toshihiko Sugiki; Kyoko Furuita; Toshimichi Fujiwara; Chojiro Kojima
Journal:  Molecules       Date:  2018-01-12       Impact factor: 4.411

Review 6.  Concepts and Core Principles of Fragment-Based Drug Design.

Authors:  Philine Kirsch; Alwin M Hartman; Anna K H Hirsch; Martin Empting
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411

7.  SPR-based fragment screening with neurotensin receptor 1 generates novel small molecule ligands.

Authors:  Sylwia Huber; Fabio Casagrande; Melanie N Hug; Lisha Wang; Philipp Heine; Lutz Kummer; Andreas Plückthun; Michael Hennig
Journal:  PLoS One       Date:  2017-05-16       Impact factor: 3.240

8.  Discovery of Cofactor Competitive Inhibitors against the Human Methyltransferase Fibrillarin.

Authors:  Yun Shi; Ibrahim M El-Deeb; Veronika Masic; Lauren Hartley-Tassell; Andrea Maggioni; Mark von Itzstein; Thomas Ve
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.